In post-weaning enteric disease management in nursery pigs, the standardised Huangbai Powder is incorporated into oral granules using wet high-shear granulation at a 10.0% w/w addition level on the dried granule mass. The API is required to meet a berberine chloride assay of 90.0–110.0% on the anhydrous basis against a declared label claim of 10.0% total alkaloids; heavy metals are controlled under Chinese Veterinary Pharmacopoeia 2020 monograph 1107 for herbal powder residues. The granulation line uses a high-shear mixer with a 300 L bowl, impeller speed 150–300 rpm, and a chopper speed 1,500–3,000 rpm; a binder solution of povidone K30 in purified water at 5.0% w/w solids is added over 180–240 seconds to bring the wet mass moisture to 8.0–12.0%. The endpoint is determined by a torque rise of 15–20 N·m above the dry-mix baseline and by a manual squeeze test showing a cohesive plug; the wet mass is passed through a 2.5 mm conical mill and dried in a fluid-bed dryer at inlet air 60–65°C to a loss on drying of ≤2.5% (USP <731>). After drying, the granules are sieved to collect the 0.8–2.0 mm fraction; fines below 0.8 mm are either recycled into the next granulation or removed. The finished granule contains 9.0–11.0 mg/g berberine alkaloid and is packed into 100 g and 500 g aluminium-foil sachets under ≤35% RH; this is an oral granule feed-top-dressing for swine. Stability testing follows VICH GL18 with long-term storage at 25°C/60% RH and accelerated storage at 40°C/75% RH in semi-permeable sachets.

What Limits Dispersibility of Berberine-Rich Veterinary Powder in Hard Drinking Water?

Dispersibility failures in broiler watering lines are most often caused by the weak aqueous solubility of the native berberine alkaloid fraction at neutral-to-alkaline pH, with precipitation accelerations above pH 6.5 and in total carbonate hardness greater than 250 mg/L CaCO₃. The formulation therefore acidifies the dry blend with anhydrous citric acid at 2.0–4.0% w/w and sodium citrate dihydrate at 0.5–1.5% w/w to buffer reconstituted solutions to pH 4.5–5.0; the API is added at 5.0–15.0% w/w of the finished dispersible powder, and the reconstituted drinking-water dilution is adjusted to deliver 0.1–0.4 mg/mL berberine alkaloid per bird daily water intake. Production consists of dry blending the API with spray-dried lactose monohydrate and colloidal silicon dioxide at 0.5% w/w in a 1,000 L double-cone blender at 12 rpm for 15 minutes; the blend is then filled into 500 g and 1 kg poly-coated foil pouches. The finished product is a water-dispersible powder for oral administration via nipple or bell drinkers, and is intended only for non-ruminant poultry where local veterinary prescription allows. The relevant compliance standard is EU Regulation 2019/6 for veterinary medicinal products, and the product is tested for dissolution using USP <711> Apparatus 2 at 50 rpm in 900 mL of pH 4.5 acetate buffer at 37°C, with a Q-value of not less than 75% at 30 minutes. Where local water alkalinity exceeds 300 mg/L CaCO₃, published data for this specific configuration is limited and a pilot reconstitution study is required before field deployment.

Sterile Injectable Manufacture: Endotoxin, Particulate, and pH Control

For injectable dosage forms, the API must be designated as sterile-grade and controlled for bacterial endotoxin with a limit of ≤0.5 EU/mg calculated from the intended maximum dose per kg body weight under the K/M approach. A 10.0 mg/mL berberine chloride-equivalent solution is prepared by dissolving the sterile API in Water for Injection preheated to 55–65°C; the solution pH is adjusted to 3.8–4.2 with 0.1 N hydrochloric acid to maintain alkaloid solubility and reduce oxidative discolouration. The bulk solution is blanketed with filtered nitrogen and passed through a 0.22 μm PVDF membrane at 0.5–1.0 bar differential pressure into a stainless-steel holding vessel; filling is performed in a Grade A isolator under EU GMP Annex 1:2022 with continuous non-viable particle monitoring at ≥0.5 μm and ≥5.0 μm. The final sterile solution is filled into 10 mL amber Type I glass vials closed with chlorobutyl stoppers; the finished product is an injectable solution for cattle and swine. Compounding and aseptic process validation follow EU GMP Annex 1, USP <85> for bacterial endotoxin, and USP <788> for particulate matter; sterility is confirmed by USP <71> membrane filtration. No terminal sterilisation is assumed; if heat sterilisation is introduced, the thermal degradation rate constant of berberine in acidic solution at 121°C must first be established by forced-degradation data.

When Feed Premix Homogeneity Falls Below a Coefficient of Variation of 5%

Premix operations producing cross-contamination-sensitive products set the target mixing uniformity at a coefficient of variation of ≤5.0% measured by sampling after ribbon blending; when the traceability sample from a 2,000 kg batch falls above 5.0%, the cause is usually differential particle-size segregation between the API and corncob carrier. The standardised Huangbai Powder is incorporated at 20.0–30.0% w/w into the intermediate premix; the intermediate is then let down into final feed at 0.5–2.0 kg per tonne of complete feed, yielding a target berberine alkaloid concentration in the final feed. The production line uses a double-shaft paddle mixer with 10-minute dry blending, followed by 5-minute post-fat addition if the feed is pelleted; after each batch, the mixer is cleaned by a flush batch of 10–20 kg ground corn to reduce carryover below 0.5% of active. The terminal finished product is a feed premix or pelleted complete feed for ruminants; compliance is derived from EU Regulation (EC) No 183/2005 laying down requirements for feed hygiene, ISO 22000 for feed safety management, and FAMI-QS certification for specialty feed ingredients. Sampling and quantification follow ISO 6497:2002 for animal feeding stuffs sampling and in-house HPLC for berberine chloride content.

Roller-Compacted Granule Interfaces and Capsule Fill Weight Drift

The as-supplied veterinary API frequently shows a Carr index of 28–35 and a Hausner ratio of 1.30–1.45, which creates dosator fill weight drift on high-speed capsule fillers when the powder bed is not granulated. A capsule formulation for companion animals is prepared at 25.0% w/w API, 57.5% w/w microcrystalline cellulose PH102, 10.0% w/w pregelatinised maize starch, 5.0% w/w crospovidone, and 2.5% w/w magnesium stearate; the first four components are roller-compacted on a Gerteis Mini-Pactor at roll force 4–8 kN/cm and gap width 1.5–2.0 mm, then milled through a 1.0 mm screen and blended with lubricant for 3 minutes. The resulting granules show a Hausner ratio of 1.15–1.25 and a bulk density of 0.52–0.60 g/mL; size 1 capsules are filled to a target fill weight of 400 mg ± 3.0% delivering 100 mg berberine chloride per capsule. The finished product is a hydroxypropyl methylcellulose capsule for oral administration to dogs and cats under veterinary prescription. Uniformity of dosage units is tested according to USP <905>, disintegration according to USP <701> in 800 mL water at 37°C with an acceptance of ≤30 minutes, and loss on drying according to USP <731> at 105°C to ≤5.0%.

Mapping Disintegration Force and Friability in Livestock Tablet Presses

Livestock tablets containing the API are compressed on a 16-station rotary press after wet granulation with 5.0% w/w hydroxypropyl methylcellulose binder solution; the formula uses 30.0% w/w API, 44.0% w/w dicalcium phosphate dihydrate, 21.0% w/w microcrystalline cellulose PH101, 4.0% w/w crospovidone, and 1.0% w/w magnesium stearate. Granules are dried at 50°C in a tray oven to moisture ≤2.5% and milled through 1.2 mm; the press is set with a precompression force of 3–5 kN and main compression force of 12–20 kN to produce tablets with hardness 60–100 N, friability ≤1.0%, and disintegration ≤15 minutes in 900 mL water at 37°C. At compression forces above 20 kN, tablets may cap due to elastic recovery of the API; below 12 kN, friability exceeds the limit. The finished product is a 500 mg immediate-release tablet for cattle, sheep, or swine, with a 150 mg berberine chloride claim per tablet. Release testing follows USP <1216> for friability, USP <701> for disintegration, and USP <905> for unit dose uniformity; the batch record includes in-process hardness checks at 15-minute intervals to detect tooling wear and granule segregation.

For Oral Solution Stability, Light Transmission and pH Hold First-Order Degradation Thresholds

When the API is dissolved in purified water for oral liquid dosing, the formulation is adjusted to 2.0–5.0 mg/mL berberine alkaloid with pH held between 3.8 and 4.2 using citric acid/sodium citrate buffer; above pH 5.5, the solution darkens and first-order degradation of berberine accelerates under fluorescent light. Sodium metabisulfite and other strong reducing agents are excluded because they reduce the quaternary ammonium alkaloid to colorless dihydro derivatives; the bulk solution is instead sparged with nitrogen and stored in amber polyethylene terephthalate bottles with headspace below 5% v/v. The manufacturing process includes dissolving the API in purified water at 40°C for 20 minutes, cooling to 25°C, filtering through a 0.45 μm polypropylene cartridge, and filling under laminar flow; in-process checks measure pH, clarity, and berberine content by HPLC before final packaging. The terminal finished product is a multi-dose oral solution for swine or poultry with a graduated pour-top cap. Compliance for multiple-dose preservation is tested by USP <51> antimicrobial effectiveness, and packaging compatibility is evaluated under USP <661.1>; stability follows VICH GL3 with storage at 25°C/60% RH and 40°C/75% RH. Light exposure data from primary packaging development indicate that amber PET reduces photodegradation to below 5.0% total impurities after 12 months.